Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.
Phase:
PHASE2
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Incyte Corporation National Heart, Lung, and Blood Institute (NHLBI)